NASDAQ:BDSX Biodesix (BDSX) Stock Price, News & Analysis → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Free BDSX Stock Alerts $1.28 -0.01 (-0.78%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$1.24▼$1.2950-Day Range$1.21▼$1.6252-Week Range$1.03▼$2.21Volume36,906 shsAverage Volume253,153 shsMarket Capitalization$124.08 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Biodesix alerts: Email Address Biodesix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside173.4% Upside$3.50 Price TargetShort InterestHealthy1.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$173,034 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.44) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.23 out of 5 starsMedical Sector508th out of 909 stocksMedical Laboratories Industry13th out of 20 stocks 3.5 Analyst's Opinion Consensus RatingBiodesix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiodesix has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.12% of the float of Biodesix has been sold short.Short Interest Ratio / Days to CoverBiodesix has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodesix has recently increased by 53.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiodesix does not currently pay a dividend.Dividend GrowthBiodesix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BDSX. Previous Next 1.3 News and Social Media Coverage News SentimentBiodesix has a news sentiment score of -0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Biodesix this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for BDSX on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows3 people have added Biodesix to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biodesix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $173,034.00 in company stock.Percentage Held by Insiders63.80% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.96% of the stock of Biodesix is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biodesix are expected to grow in the coming year, from ($0.44) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biodesix is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biodesix is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiodesix has a P/B Ratio of 25.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad GoldenCrest MetalsExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.Learn More Now About Biodesix Stock (NASDAQ:BDSX)Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.Read More BDSX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BDSX Stock News HeadlinesApril 24, 2024 | businesswire.comBiodesix to Report First Quarter 2024 Financial Results on May 8, 2024April 17, 2024 | americanbankingnews.comBiodesix (NASDAQ:BDSX) and Personalis (NASDAQ:PSNL) Critical AnalysisApril 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.April 13, 2024 | finance.yahoo.comThe recent US$4.0m market cap decrease is likely to have disappointed insiders invested in Biodesix, Inc. (NASDAQ:BDSX)April 9, 2024 | businesswire.comBiodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual MeetingApril 5, 2024 | markets.businessinsider.comS&P 500 Gains Over 1%; GCT Semiconductor Shares Spike HigherApril 5, 2024 | markets.businessinsider.comGold Surges Over 1%; Biodesix Shares PlummetApril 5, 2024 | businesswire.comBiodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private PlacementApril 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.March 25, 2024 | businesswire.comBiodesix Announces New Master Collaborative Research Agreement with Leading US Cancer CenterMarch 4, 2024 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Q4 2023 Earnings Call TranscriptMarch 3, 2024 | finance.yahoo.comBiodesix Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 1, 2024 | finance.yahoo.comBiodesix Inc (BDSX) Reports Strong Growth in Lung Diagnostic Test Volume and Gross Profit MarginMarch 1, 2024 | businesswire.comBiodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business HighlightsFebruary 26, 2024 | businesswire.comBiodesix to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 16, 2024 | finance.yahoo.comBiodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024February 16, 2024 | businesswire.comBiodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024February 13, 2024 | finance.yahoo.comBiodesix Inc CEO Scott Hutton Sells 64,390 SharesFebruary 2, 2024 | finance.yahoo.comOne Biodesix Insider Raised Their Stake In The Previous YearNovember 14, 2023 | finance.yahoo.comBiodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw MethodNovember 9, 2023 | finance.yahoo.comBiodesix to Participate in Two Upcoming Investor Conferences in NovemberNovember 7, 2023 | finance.yahoo.comBiodesix Announces Third Quarter 2023 Results and HighlightsNovember 6, 2023 | markets.businessinsider.comHere's what Wall Street expects from Biodesix's earningsOctober 24, 2023 | finance.yahoo.comBiodesix to Report Third Quarter 2023 Financial Results on November 7, 2023October 3, 2023 | finance.yahoo.comBiodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual MeetingSeptember 7, 2023 | finance.yahoo.comBiodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung CancerAugust 26, 2023 | finance.yahoo.comJack Schuler Spends US$217k On Biodesix StockSee More Headlines Receive BDSX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/01/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:BDSX CUSIPN/A CIK1439725 Webwww.biodesix.com Phone303-417-0500FaxN/AEmployees217Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$3.50 Low Stock Price Target$3.50 Potential Upside/Downside+173.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,150,000.00 Net Margins-106.23% Pretax Margin-106.23% Return on Equity-29,379.44% Return on Assets-58.96% Debt Debt-to-Equity Ratio7.69 Current Ratio1.19 Quick Ratio1.19 Sales & Book Value Annual Sales$49.09 million Price / Sales2.53 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book25.60Miscellaneous Outstanding Shares96,940,000Free Float35,093,000Market Cap$124.08 million OptionableOptionable Beta1.13 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Scott Hutton (Age 52)President, CEO & Director Comp: $632kMs. Robin Harper Cowie (Age 44)CFO, Secretary & Treasurer Comp: $390.87kDr. Heinrich RöderFounder & CTOMr. Christopher VazquezVP, Controller & Chief Accounting OfficerMr. Mark DeBlockVice President of SalesMr. Robbie LuntSenior Director of MarketingMs. Jessica OlbrichtSenior Director of Human ResourcesDr. Gary Anthony Pestano Ph.D. (Age 57)Chief Development Officer Ms. Bobbi CoffinChief Growth OfficerDr. James R. Jett M.D.Co-Chief Medical OfficerMore ExecutivesKey CompetitorsPersonalisNASDAQ:PSNLEnzo BiochemNYSE:ENZRenalytixNASDAQ:RNLXAkuminNASDAQ:AKUMQExagenNASDAQ:XGNView All CompetitorsInsiders & InstitutionsOpaleye Management Inc.Bought 40,927 shares on 2/15/2024Ownership: 0.549%Oracle Investment Management Inc.Bought 18,863 shares on 2/14/2024Ownership: 0.067%AIGH Capital Management LLCSold 247,752 shares on 2/12/2024Ownership: 5.149%Scott HuttonSold 29,708 sharesTotal: $49,315.28 ($1.66/share)Robin Harper CowieSold 8,699 sharesTotal: $14,440.34 ($1.66/share)View All Insider TransactionsView All Institutional Transactions BDSX Stock Analysis - Frequently Asked Questions Should I buy or sell Biodesix stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biodesix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BDSX shares. View BDSX analyst ratings or view top-rated stocks. What is Biodesix's stock price target for 2024? 3 brokers have issued 12 month price objectives for Biodesix's shares. Their BDSX share price targets range from $3.50 to $3.50. On average, they expect the company's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 173.4% from the stock's current price. View analysts price targets for BDSX or view top-rated stocks among Wall Street analysts. How have BDSX shares performed in 2024? Biodesix's stock was trading at $1.84 at the beginning of 2024. Since then, BDSX stock has decreased by 30.4% and is now trading at $1.28. View the best growth stocks for 2024 here. Are investors shorting Biodesix? Biodesix saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 277,400 shares, an increase of 53.2% from the March 15th total of 181,100 shares. Based on an average daily volume of 163,400 shares, the short-interest ratio is currently 1.7 days. Approximately 1.1% of the shares of the company are short sold. View Biodesix's Short Interest. When is Biodesix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our BDSX earnings forecast. How were Biodesix's earnings last quarter? Biodesix, Inc. (NASDAQ:BDSX) announced its earnings results on Friday, March, 1st. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The company earned $14.67 million during the quarter, compared to analyst estimates of $15.76 million. Biodesix had a negative trailing twelve-month return on equity of 29,379.44% and a negative net margin of 106.23%. What guidance has Biodesix issued on next quarter's earnings? Biodesix updated its FY 2024 earnings guidance on Friday, March, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $65.0 million-$68.0 million, compared to the consensus revenue estimate of $64.5 million. When did Biodesix IPO? Biodesix (BDSX) raised $76 million in an IPO on Wednesday, October 28th 2020. The company issued 4,200,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley and William Blair served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. How do I buy shares of Biodesix? Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BDSX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingElon Musk’s Controversial New Project: “Apollo”InvestorPlaceNew Trump BombshellThe Freeport SocietyThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodesix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
